Concepedia

Joseph Chen

JC

Statistics

Publications

16

Citations

2K

H-Index

15

Active since

2004

Affiliations

Pfizer (United States)(Current)

Massachusetts General Hospital

Vall d'Hebron Institute of Oncology

Peter MacCallum Cancer Centre

University of California San Diego

Joseph Chen is an author at Pfizer (United States) specializing in medicine, pharmacology, and oncology.

Publications per year

2004–2023

16

Publications

16

Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study

Benjamin Solomon, Benjamin Besse, Todd M. Bauer et al. · The Lancet Oncology · 2018 · 789 citations

Medicine, Oncology, Medical Oncology +10

Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial

Alice T. Shaw, Enriqueta Felip, Todd M. Bauer et al. · The Lancet Oncology · 2017 · 649 citations · Full text

Medicine, Oncology, Pharmacology +14

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results

Kelly C. Goldsmith, Julie R. Park, Kimberly Kayser et al. · Nature Medicine · 2023 · 125 citations · Full text

Medicine, Oncology, Pharmacology +10

Diagnosis, Evaluation, and Treatment of Adenomyosis

Kimberly A. Kho, Joseph Chen, Lisa M. Halvorson · JAMA · 2021 · 94 citations

Medicine, Surgery, Diagnostic Pathology +5

Pharmacokinetics of Lorlatinib After Single and Multiple Dosing in Patients with Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer: Results from a Global Phase I/II Study

Joseph Chen, Melissa O’Gorman, Lee P. James et al. · Clinical Pharmacokinetics · 2021 · 34 citations · Full text

Medicine, Oncology, Pharmacology +13

1–5 of 16